Ann: Letter to Shareholders, page-200

First 200 Last

Share
Profile

Follow
Davisite

19,027 Posts.

5823

13/07/19

07:43

Post #: 39504049
Share

Originally posted by Southoz ↑

I’ll have a crack at explaining it Davisite – because I also don’t see a problem with this figure and how BIT have applied that statistical test.

From the figure CD8 mean levels do appear to increase in the first few weeks in the bit225 cohort compared to placebo. This fits with BITs theory those patients were exposed to a unique antigen source.

And at the third time point guess what these means levels were statistically different. Funnily enough this was tested using a Welsh T-test which is more conservative than a student t-test and less prone to type one error.

This tells you one of two things.

Either the analyst was very skillful at using the most appropriate t-test in this particular situation (where you had unequal sample sizes) or they had dumb luck because they were using the R package which spits out the Welch t-test by default in contrast to most other packages which default to the student t-test.

Which ever way - skill or dumb luck the test is appropriate for the data and in the context of this trial.

Your concerns about post-hoc or multiple testing are just misplaced. The trial was exploratory – generate hypotheses for confirmatory testing – and the data is suggestive of exactly what BIT thought (hoped) was going on.

The fallacy in what you are implying is that somehow due to this post-hoc multiple statistical testing nonsense this finding of initial CD8 level increase has poor positive predictive power – ie wont replicate because it isn’t true because of the approach taking to statistical analysis.

This is just wrong – what is determining the reproducibility of this finding is the basic design (the strengths / weaknesses) of the trial – not whether or not some statistical test has a p value of whatever it is.

Hopefully you can understand what I have outlined above; even though I don’t claim to be an expert about anything. So I just must be good at googling stuff. Perhaps you can clarify for people what exactly is your experience in the statistical analysis, reporting or reviewing of clinical trial data and methods.

Expand

@Southoz I am happy to engage with you on this topic as I think it will be very enlightening to all here, but before I do will you agree to engage in a detailed response. Every time you have posted here in the past you make one post and then disappear and don't respond to any of my follow up posts.

I have said nothing about replication of the data, but that post-hoc analysis doesn't allow you to say anything about the data except suggest addition experiements that could be performed. BIT have zero data to suggest that the one data point that was different was due anything other than pure chance.

BIT Price at posting: 8.4¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

ARN

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Shekel Brainweigh and Calmer Co lead innovations in the retail space

RCE

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

There are more pages in this discussion • 405 more messages in this thread...

First 200 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 3.5¢		Change 0.002(6.06%)		Mkt cap ! $31.57M

Open	High	Low	Value	Volume
3.3¢	3.5¢	3.3¢	$19.27K	566.6K

Buyers (Bids)

No.	Vol.	Price($)
1	299989	3.4¢

Sellers (Offers)

Price($)	Vol.	No.
3.5¢	371664	3

View Market Depth

No.	Vol.	Price($)
1	299989	0.034
3	240016	0.033
2	242406	0.032
6	600480	0.031
9	670666	0.030

Price($)	Vol.	No.
0.035	371664	3
0.036	65500	1
0.037	767816	3
0.039	430546	2
0.040	113240	2

Last trade - 16.10pm 15/07/2024 (20 minute delay)

BIT (ASX) Chart

Ann: Letter to Shareholders, page-200

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Letter to Shareholders, page-200

Top Stories

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News